Arcus Biosciences (RCUS) Non Operating Income (2017 - 2026)

Arcus Biosciences' Non Operating Income history runs 10 years deep, the most recent figure standing at $6.0 million for Q1 2026.

• On a quarterly basis, Non Operating Income fell 40.0% year-over-year to $6.0 million in Q1 2026; TTM through Mar 2026 was $29.0 million, a 36.96% decrease from a year earlier, with the FY2025 full-year figure at $33.0 million, down 31.25% from the prior year.
• Non Operating Income fell to $6.0 million in Q1 2026 per RCUS's latest filing, from $8.0 million in the prior quarter.
• Across five years, Non Operating Income topped out at $13.0 million in Q2 2024 and bottomed at $191000.0 in Q1 2022.
• The 5-year median for Non Operating Income is $8.0 million (2023), against an average of $8.2 million.
• Across the five-year window, Non Operating Income surged 4088.48% in 2023 and tumbled 46.15% in 2025, its largest moves.
• Year by year, Non Operating Income stood at $7.0 million in 2022, then surged by 57.14% to $11.0 million in 2023, then declined by 9.09% to $10.0 million in 2024, then dropped by 20.0% to $8.0 million in 2025, then decreased by 25.0% to $6.0 million in 2026.
• Per Business Quant, the three latest RCUS Non Operating Income figures stand at $6.0 million (Q1 2026), $8.0 million (Q4 2025), and $7.0 million (Q3 2025).